Anaptysbio (ANAB)
51.63
0.00 (0.00%)
Upcoming Events
Latest Headlines
H.C. Wainwright Assumes AnaptysBio (ANAB) at Buy
June 10, 2026 6:07 AM - StreetInsider
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 9, 2026 5:09 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 8, 2026 5:20 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 5, 2026 5:23 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 5, 2026 12:36 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 3, 2026 5:17 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 2, 2026 4:37 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
June 1, 2026 5:50 PM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: May 29
May 29, 2026 4:15 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 29, 2026 4:11 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 28, 2026 5:52 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 27, 2026 4:47 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 26, 2026 4:30 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 22, 2026 4:05 PM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: May 18
May 21, 2026 4:10 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 21, 2026 4:02 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 19, 2026 5:37 PM - SEC Filing
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:30 PM - SEC Filing
Form 144 ANAPTYSBIO, INC Filed by: MULROY DENNIS
May 15, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G ANAPTYSBIO, INC Filed by: Sirenia Capital Management LP
May 15, 2026 8:10 AM - SEC Filing
Form 4 ANAPTYSBIO, INC For: May 11 Filed by: Hughes Owen
May 13, 2026 5:50 PM - SEC Filing
Form 3 ANAPTYSBIO, INC For: May 11 Filed by: Hughes Owen
May 13, 2026 5:50 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: May 11 Filed by: Murphy Christopher M.
May 13, 2026 5:49 PM - SEC Filing
Form 3 ANAPTYSBIO, INC For: May 11 Filed by: Murphy Christopher M.
May 13, 2026 5:48 PM - SEC Filing
AnaptysBio (ANAB) PT Raised to $76 at UBS
May 13, 2026 8:39 AM - StreetInsider
AnaptysBio (ANAB) PT Raised to $75 at Barclays
May 13, 2026 4:22 AM - StreetInsider
AnaptysBio, Inc. (ANAB) Misses Q1 EPS by 88c
May 12, 2026 5:16 PM - StreetInsider
Form 10-Q ANAPTYSBIO, INC For: Mar 31
May 12, 2026 4:20 PM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: May 12
May 12, 2026 4:18 PM - SEC Filing
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026 4:15 PM - StreetInsider
Form 8-K ANAPTYSBIO, INC For: May 11
May 11, 2026 4:06 PM - SEC Filing
AnaptysBio names Chris Murphy CFO, adds Owen Hughes to board
May 11, 2026 9:15 AM - StreetInsider
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
May 11, 2026 9:15 AM - Globe NewsWire
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
May 4, 2026 4:15 PM - StreetInsider
AnaptysBio (ANAB) PT Lowered to $93 at Piper Sandler
May 4, 2026 8:04 AM - StreetInsider
Form 4 ANAPTYSBIO, INC For: Apr 27 Filed by: GRAY SUSANNAH
April 29, 2026 4:05 PM - SEC Filing
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
April 28, 2026 7:13 PM - PR NewsWire
Form 10-K/A ANAPTYSBIO, INC For: Dec 31
April 28, 2026 4:11 PM - SEC Filing
Form 8-K/A ANAPTYSBIO, INC For: Apr 20
April 24, 2026 4:19 PM - SEC Filing
Delaware court dismisses Tesaro breach claim against Anaptys
April 24, 2026 3:41 PM - StreetInsider
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
April 24, 2026 3:40 PM - Globe NewsWire
AnaptysBio (ANAB) PT Raised to $66 at Leerink Partners
April 24, 2026 7:19 AM - StreetInsider
Form 4/A ANAPTYSBIO, INC For: Apr 20 Filed by: Faga Daniel
April 23, 2026 7:21 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: Orwin John A
April 22, 2026 6:36 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: Schmid John P.
April 22, 2026 6:35 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: RENTON HOLLINGS
April 22, 2026 6:34 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Apr 20 Filed by: Faga Daniel
April 22, 2026 6:33 PM - SEC Filing
AnaptysBio (ANAB) PT Lowered to $63 at Barclays
April 22, 2026 2:48 AM - StreetInsider
AnaptysBio (ANAB) PT Lowered to $60 at UBS Following Spinoff of Biopharma Business
April 21, 2026 9:25 AM - StreetInsider
Form 8-K ANAPTYSBIO, INC For: Apr 20
April 20, 2026 5:25 PM - SEC Filing
AnaptysBio completes spinoff of First Tracks, focuses on royalties
April 20, 2026 9:16 AM - StreetInsider
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
April 20, 2026 9:15 AM - StreetInsider
Form 3 ANAPTYSBIO, INC For: Mar 26 Filed by: GRAY SUSANNAH
April 3, 2026 4:01 PM - SEC Filing
AnaptysBio (ANAB) PT Raised to $69 at JPMorgan
April 2, 2026 9:58 AM - StreetInsider
Form 4 ANAPTYSBIO, INC For: Mar 30 Filed by: Schmid John P.
April 1, 2026 9:28 PM - SEC Filing
AnaptysBio (ANAB) PT Raised to $95 at Piper Sandler
March 31, 2026 9:35 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)
March 31, 2026 6:42 AM - StreetInsider
Form 144 ANAPTYSBIO, INC Filed by: Schmid John P.
March 30, 2026 5:29 PM - SEC Filing
Form 4 ANAPTYSBIO, INC For: Mar 25 Filed by: Faga Daniel
March 27, 2026 8:16 PM - SEC Filing
Form 8-K ANAPTYSBIO, INC For: Mar 26
March 27, 2026 9:20 AM - SEC Filing
AnaptysBio authorizes $100 million stock buyback plan
March 27, 2026 9:00 AM - StreetInsider
First Tracks Biotherapeutics secures $145 million private placement ahead of spinoff
March 27, 2026 9:00 AM - StreetInsider
AnaptysBio board approves First Tracks Biotherapeutics spin-off
March 27, 2026 9:00 AM - StreetInsider
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
March 27, 2026 9:00 AM - StreetInsider
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
March 27, 2026 9:00 AM - StreetInsider
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
March 27, 2026 9:00 AM - StreetInsider
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: VANGUARD GROUP INC
March 26, 2026 3:45 PM - SEC Filing
AnaptysBio (ANAB) PT Raised to $90 at UBS
March 17, 2026 6:13 AM - StreetInsider
Full Article List
